icon-folder.gif   Conference Reports for NATAP  
  EASL 48th Annual Meeting
April 24th - 28th 2013
The Netherlands, Amsterdam
Back grey_arrow_rt.gif
In Vitro Resistance to ALS-2200, a Potent Nucleotide Polymerase Inhibitor for the Treatment of Chronic Hepatitis
  Reported by Jules Levin
EASL 2013 April 28 Amsterdam
EASL: ALS-2200, A Novel Once-daily Nucleotide HCV Polymerase Inhibitor, Demonstrated Potent Antiviral Activity In Treatment-na´ve Patients with Compensated Cirrhosis or Genotype 2-4 Chronic Hepatitis C - (04/27/13) median 4 to 4.5 log HCV RNA reductions were seen in this study presented in a poster at EASL.
EASL: ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection - (04/23/13)
C Tan, H., Jekle, A., Kang, H., Moy, C., Deval, J., *Tigges, A., *Zhang, E., *Jiang, M., *Ardzinski, A., Dyatkina, N., Wang, G., *Rijnbrand R., *Kieffer, T., Blatt, L.M., Beigelman, L., Smith, D.B. Symons, J.A. Alios BioPharma, Incorporated, South San Francisco, CA and *Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA